Introduction Lipid nanoparticles (LNPs) have rapidly emerged as the leading non-viral delivery platform for nucleic acid therapeutics, underscored by the clinical and commercial success of mRNA-based COVID-19 vaccines. Unlike conventional small-molecule drugs,Read More…